Your session is about to expire
What is Cyclosporine
CyclosporineThe Generic name of this drug
Treatment SummaryCyclosporine is a medication that helps prevent organ transplant rejection and treats inflammation and autoimmune conditions. It is derived from a fungus called Beauveria nivea and was approved by the FDA in 1983. It is now produced by Novartis as various products.
Sandimmuneis the brand name
Cyclosporine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sandimmune
Cyclosporine
1983
68
Approved as Treatment by the FDA
Cyclosporine, also known as Sandimmune, is approved by the FDA for 27 uses which include Transplantation and Glomerulosclerosis, Focal Segmental .Transplantation
Glomerulosclerosis, Focal Segmental
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Therapeutic immunosuppression
Focal Segmental Glomerulosclerosis (FSGS)
Helps manage Focal Segmental Glomerulosclerosis (FSGS)
Glomerulosclerosis
Helps manage Glomerulosclerosis
Not responsive to other therapy
Helps manage Not responsive to other therapy
Liver Transplant Rejection
Heart Transplant Rejection
Kidney Transplant Rejection
severe, active Rheumatoid arthritis
Helps manage severe, active Rheumatoid arthritis
Patients who do not adequately respond to methotrexate alone
Used to treat Patients who do not adequately respond to methotrexate alone in combination with Methotrexate
Prophylaxis against heart transplant rejection
Liver
Steroid Resistant Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Steroid Dependent Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
severe, recalcitrant Plaque psoriasis
Helps manage severe, recalcitrant Plaque psoriasis
Prophylaxis against graft versus host disease
Heymann Nephritis
Helps manage Glomerulonephritis, Membranous
Bone Marrow Transplantation
Chronic Graft Versus Host Disease
Prophylaxis against stem cell transplant rejection
Rheumatoid Arthritis
Helps manage severe, active Rheumatoid arthritis
Nephrotic Syndrome
Helps manage Nephrotic Syndrome
Bone Marrow
Kidney Transplantation
Nephrotic Syndrome
Helps manage Steroid Resistant Nephrotic Syndrome
Nephrotic Syndrome
Helps manage Steroid Dependent Nephrotic Syndrome
Effectiveness
How Cyclosporine Affects PatientsCyclosporine is a drug used to prevent organ and bone marrow transplants from being rejected, as well as to control serious immune reactions caused by autoimmune diseases. Common side effects include excessive hair growth, swollen gums, and high cholesterol levels. There is some controversy around the drug potentially damaging your kidneys.
How Cyclosporine works in the bodyCyclosporine is a medication that reduces inflammation. It does this by blocking a receptor in cells called cyclophilin-1. This stops the nuclear factor of activated T cells from being activated. This is important because NF-AT helps create cytokines which cause inflammation. Cyclosporine also stops the production of IL-2, which is necessary for the activation and growth of T cells. Finally, it decreases the levels of other factors related to T helper cell functioning and thymocyte development.
When to interrupt dosage
The prescribed amount of Cyclosporine is contingent upon the determined condition, including Interstitial Cystitis, Focal Segmental Glomerulosclerosis (FSGS) and Excessive tearing. The dosage is dependent on the administration approach (e.g. Liquid - Intravenous or Ophthalmic; Topical) specified in the following table.Condition
Dosage
Administration
Ulcerative Colitis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Juvenile arthritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Therapeutic immunosuppression
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Patients who do not adequately respond to methotrexate alone
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Conjunctivitis, Allergic
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Heymann Nephritis
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Dry Eye Syndromes
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Cystitis, Interstitial
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Bone Marrow
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Rosacea
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Chronic Graft Versus Host Disease
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Organ Transplantation
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Prophylaxis against stem cell transplant rejection
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Not responsive to other therapy
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Nephrotic Syndrome
0.5 mg/mL, , 100.0 mg/mL, 25.0 mg, 50.0 mg, 100.0 mg, 50.0 mg/mL, 10.0 mg, 0.05 %, 2.5 mg/mL, 0.005 mg/mL, 1.0 mg/mL, 0.1 %, 0.9 mg/mL, 0.0009 mg/mL, 0.09 %
, Ophthalmic, Emulsion, Emulsion - Ophthalmic, Oral, Solution, Solution - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Capsule, Capsule - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Liquid - Oral, Topical, Liquid - Topical, Liquid - Ophthalmic, Ophthalmic; Topical, Solution / drops - Ophthalmic; Topical, Solution / drops, Solution - Ophthalmic, Emulsion - Ophthalmic; Topical
Warnings
Cyclosporine ContraindicationsCondition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Psoriasis
Do Not Combine
Abnormal Renal Function
Do Not Combine
Hypertensive disease
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Cyclosporine may interact with Pulse Frequency
Common Cyclosporine Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Cyclosporine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Cyclosporine.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Cyclosporine.
Aliskiren
Major
The serum concentration of Aliskiren can be increased when it is combined with Cyclosporine.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Cyclosporine.
Cyclosporine Toxicity & Overdose RiskThe lowest toxic dose of cyclosporine in rats is 1480mg/kg and in humans is 12mg/kg. An overdose of cyclosporine may cause nausea, flushing, tremor, vertigo, vomiting, anorexia, and a feeling of increased body girth. If an overdose occurs, forced emesis and gastric lavage should be administered within two hours. Dialysis and charcoal hemoperfusion are not effective at removing cyclosporine from the body.
Cyclosporine Novel Uses: Which Conditions Have a Clinical Trial Featuring Cyclosporine?
81 active clinical trials are pursuing the potential of Cyclosporine to mitigate Chronic Graft Versus Host Disease, Kidney Diseases and Ulcerative Colitis.Condition
Clinical Trials
Trial Phases
Therapeutic immunosuppression
0 Actively Recruiting
Rheumatoid Arthritis
0 Actively Recruiting
Bone Marrow
1 Actively Recruiting
Early Phase 1
severe, recalcitrant Plaque psoriasis
0 Actively Recruiting
Nephrotic Syndrome
4 Actively Recruiting
Phase 2, Not Applicable, Phase 3
Disease
0 Actively Recruiting
Prophylaxis against graft versus host disease
0 Actively Recruiting
Liver
0 Actively Recruiting
Heymann Nephritis
3 Actively Recruiting
Phase 2, Phase 1
Glomerulosclerosis
0 Actively Recruiting
Prophylaxis against heart transplant rejection
0 Actively Recruiting
Organ Transplantation
0 Actively Recruiting
Excessive tearing
0 Actively Recruiting
Transplantation
0 Actively Recruiting
Kidney Transplantation
0 Actively Recruiting
Lupus Nephritis
22 Actively Recruiting
Phase 3, Phase 2, Phase 1
Not responsive to other therapy
0 Actively Recruiting
Glomerulosclerosis, Focal Segmental
12 Actively Recruiting
Not Applicable, Phase 3, Early Phase 1, Phase 2, Phase 1
Uveitis
3 Actively Recruiting
Not Applicable, Phase 1, Phase 3
Nephrotic Syndrome
0 Actively Recruiting
Cyclosporine Reviews: What are patients saying about Cyclosporine?
5Patient Review
12/20/2014 I had severe psoriasis 95 percent of my body, and after just three months on this medication, most of it has cleared up. I'm now down to a smaller quantity. Side effects are minimal compared to the others who posted comments. Fatigue, some hair loss, higher blood pressure. I hope I can go off this soon.
5Patient Review
1/1/2016 I received a transplant 25 years ago and have had no issues since. Just the normal problems that come with age.
4.3Patient Review
5/16/2014 After three weeks of using this medication, my eczema was completely gone. However, I developed a boil that led to an infection. As a result, I had to discontinue use and go to the emergency room.
3.3Patient Review
2/21/2013 The fatigue from this treatment is really bad, and it's also made me feel slow mentally.
3Patient Review
9/1/2022 I've had some really unpleasant side effects from taking Cyclosporine. The smell of the pill is awful, and I've been dealing with nausea and abdominal pain that has made it hard to sleep.
Patient Q&A Section about cyclosporine
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is cyclosporine is a steroid?
"Cyclosporine is a safe steroid-sparing agent to use topically for prolonged periods of time,” Dr."
Answered by AI
What is the drug cyclosporine used for?
"It works by weakening the body's natural defense (immune system) so that the transplanted organ is not rejected.
Cyclosporine is used in combination with other medications to prevent the body from rejecting a transplanted organ. It is classified as an immunosuppressive agent and works by weakening the body's immune system so that the transplanted organ is not rejected."
Answered by AI
Which class of drug is cyclosporine?
"This class of medication is designed to weaken the immune system by reducing the activity within it. This can help to prevent the body from attacking transplanted organs, for example."
Answered by AI
What are the side effects of taking cyclosporine?
"High blood pressure, increased hair growth, swollen or inflamed gums, numbness or tingling of the hands or feet, and other common side effects like tremors, restlessness, stomach upset, nausea, cramps, diarrhea, headache, and changes in blood sugar."
Answered by AI
Clinical Trials for Cyclosporine
Other Trials to Consider
Popular Categories
Learn More About These Treatments
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.